Navigation Links
Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
Date:12/6/2010

Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Children's Research Hospital and UCL (University College London) to correct the inherited bleeding disorder.

This trial was designed primarily as a safety test, with low and intermediate doses of the vector expected to produce little detectable Factor IX. The Factor IX protein helps the blood form clots. Individual with hemophilia B lack adequate levels of this clotting factor. The first participant in the open-label Phase I/II trial had an unexpectedly high level of Factor IX expression after receiving the lowest dose of the vector being tested in this study. Levels of the Factor IX protein rose from less than 1 percent to 2 percent of normal after the experimental vector was infused into the patient.

The patient's Factor IX production remains elevated more than nine months later. Since the infusion the patient has also not suffered any spontaneous joint bleeds or needed prophylactic treatment.

Study data was presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) by Amit Nathwani, M.D., Ph.D., UCL Department of Hematology, and National Health Service Blood and Transplant, UK, the study's first author. Andrew Davidoff, M.D., chair of the St. Jude Department of Surgery, is the senior author.

Work on the vector began more than 10 years ago in the St. Jude laboratory of Arthur Nienhuis, M.D., member of the Department of Hematology and a study co-author. The collaboration continued after Nathwani returned to London.

The trial vector was made by packaging a codon-optimized version of the Factor IX gene into a member of the adeno-associated virus (AAV) family known as AAV8. AAV8 was picked because the incidence of natural infection with AAV8 is low and, like other AAVs, targets liver cells but does not integrate into the patient's
'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
2. U of M researcher helps unlock 30 new genes responsible for early onset puberty
3. UGA researchers identify key enzyme that regulates the early growth of breast cancer cells
4. PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
5. Arsenic early in treatment improves survival for leukemia patients
6. Brookhaven chemist Jacob Hooker receives Presidential Early Career Award
7. Studying the metabolome of smokers, Lombardi researchers find early signs of damage
8. UV light nearly doubles vacuums effectiveness in reducing carpet microbes
9. Found: First complete remains of early sauropod dinosaur
10. Early role of mitochondria in AD may help explain limitations to current beta amyloid hypothesis
11. JCI online early table of contents: Oct. 11, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... Medical Branch at Galveston are the first to ... cervical cancer should begin colorectal cancer screening earlier ... finding a high incidence of secondary colorectal cancers ... new recommendations that the younger women in this ... after their initial cervical cancer diagnosis instead of ...
(Date:4/17/2014)... View of Domestication," a special feature of The ... ( PNAS ) published April 29, raises a ... deep history that most of us take for granted. ... in many spots around the globe shifted from hunting ... and plants. , It seems so straightforward and yet ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... one of the most important prerequisites for a positive self ... rather than the exception that children and young people are ... or subject to bullying are particularly critical of their appearance ... long period. This is revealed in a new thesis in ...
... Prevention (CDC) today released new infection control recommendations ... (KPC)-Producing Organisms, one of the most ... that infections with these highly resistant bacteria are ... In Guidance for Control of Infections with Carbapenem-Resistant ...
... the media. A new study by Dr. Yaniv Levyatan ... of Israel,s National Security College, describes how our side ... "Information warfare" plays a crucial role in ... conventional weapons. Therefore, the information warfare against terrorist organizations ...
Cached Biology News:Children who are dissatisfied with their appearance often have problems with their peer group 2Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms 2Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... highlights for the three and six month ... experienced a strong second quarter with the ... therapy treatment in,refractory head and neck cancer ...
... DIEGO, July 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... quarter 2008,financial results after the NASDAQ Global Market ... Jack Lief, Arena,s President and Chief,Executive Officer, and ... Financial Officer, will host a conference call at ...
... Abt Associates has been,ranked 19th in the Marketing News ... Research firms. The listing is based on 2007 revenue ... for,calendar 2007 was $55.1 million. Total company revenues for ... Abt Associates market research activities are carried out ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 9Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 10Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 11Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 12Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 13Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 14Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 15Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 16Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 17Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 18Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 19Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 20Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 21Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 22Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 23Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 24Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 25Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 26Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 27Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 28Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 29Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 30Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 31Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 32Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 33Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 2Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 3Abt Associates Ranked One of Top 20 U.S. Market Research Firms 2
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: